Brief: Late-Breaking Data At EADV Of Esk-001 Demonstrate Significant Responses

Alumis

27/09/2024 14:17

Sept 27 (Reuters) - Alumis Inc  ALMS.O :
    * LATE-BREAKING DATA AT EADV OF ESK-001, AN ORAL TYK2
INHIBITOR
FOR THE TREATMENT OF PSORIASIS, DEMONSTRATE SIGNIFICANT
RESPONSES WITH SUSTAINED INCREASES OVER 28 WEEKS IN PHASE 2 OLE
STUDY
    * ALUMIS : 28-WEEK DATA SHOW ESK-001 WAS GENERALLY WELL
TOLERATED
& MOST PATIENTS TREATED WITH TOP DOSE OF 40 MG TWICE DAILY
ACHIEVED PASI 75
    * ALUMIS: FULL 52-WEEK PHASE 2 OLE DATASET EXPECTED 1H 2025;
PHASE
3 CLINICAL PROGRAM

Source text for Eikon:  ID:nGNX782Dgc 
Further company coverage:  ALMS.O 

 ((Reuters.Briefs@thomsonreuters.com;))